Prostaglandin-Associated Periorbitopathy (PAP)

Types
Causes
Symptoms
Diagnostic tests
Non-pharmacological treatments
Drug treatments
Dietary molecular supplements
Regenerative / stem-cell drugs
Surgeries/procedures
Preventions
When to see a doctor
Foods to favor and to limit/avoid
FAQs

Prostaglandin-Associated Periorbitopathy (PAP) is a collection of look-and-feel changes around the eyes that can happen in some people who use prostaglandin eye drops for glaucoma or eyelash-growth serums containing similar ingredients. The changes usually include a sunken look to the upper eyelids (deepened upper eyelid sulcus), mild sinking of the eyeball (enophthalmos), droopy lids (ptosis), and shrinking of the fat around the eyes (periorbital fat atrophy). Skin and lashes can also change: the skin may look darker and lashes may grow longer and thicker. These effects are typically caused by prostaglandin F-receptor (FP) agonists (such as bimatoprost, latanoprost, travoprost, tafluprost). Doctors often spot PAP when only one eye is treated and the two sides of the face begin to look different. In many people, the changes improve after stopping or switching the drug, though this is not guaranteed and may take months. EyeWikiAmerican Academy of OphthalmologyPMCPubMed

FP-receptor stimulation in orbital tissues can slow down the making of new fat cells and push the tissues to remodel, likely by inhibiting adipogenesis and altering collagen and matrix enzymes. In short, the tissues lose volume and tighten. This is the opposite of what happens in diseases where orbital fat grows. PMCNatureTaylor & Francis Online

Prostaglandin-associated periorbitopathy is a group of changes that happen around the eyelids and the eye socket after using prostaglandin eye drops for glaucoma. These changes affect the skin, the eyelids, the fat around the eyes, and sometimes the eye’s position. Doctors first noticed it when only one eye was treated and that eye started to look different from the other. Typical changes include a deeper fold in the upper eyelid, drooping of the upper eyelid, loss of the puffy lower-lid bags, a slightly sunken eye, tighter eyelids, and visible eyelid blood vessels. Eyelashes can also grow longer and thicker, and the skin or iris can look darker. These findings are well described in ophthalmology references and reviews. EyeWikiAmerican Academy of Ophthalmology

Why it happens

Prostaglandin glaucoma drops work by binding a receptor called the FP receptor. This action lowers eye pressure, which is good for glaucoma. The same action also affects fat cells in the eyelid and orbit. It tells young fat cells not to mature and makes existing fat cells shrink. When the fat pads shrink, the upper eyelid crease looks deeper and the eye can look slightly sunken. Studies show smaller orbital fat volume on MRI and lab studies show blocked fat formation with FP-receptor signaling. This is the most accepted explanation today. PMC+1Nature

PAP is not rare once you look for it carefully. It often shows up after weeks to months, and it becomes easier to recognize if only one eye is treated. Many patients do not notice a problem because the change is slow and often affects both eyes in the same way. Stopping the prostaglandin or switching to a different medicine can lead to partial or full improvement, sometimes within one to two months, although the timing varies by person. EyeWiki

Types

Doctors group PAP in several simple ways so everyone can talk about it clearly.

By the main feature you see first.
Some people mainly show eyelid changes like a deeper upper-lid fold or a droopy lid. Others mainly show orbital changes like a mild sunken eye and slimmer lower-lid bags. This grouping helps focus the exam on what is most visible in that person. EyeWiki
By side and symmetry.
PAP can be unilateral when only one eye gets drops or gets more exposure. PAP can be bilateral and look symmetric when both eyes get drops. Unilateral cases are easier to spot because the two sides look different. EyeWiki
By time of onset.
Early PAP can appear within weeks to a few months of starting treatment. Established PAP appears after months to years and usually looks more obvious. This time-based view helps set expectations for follow-up. EyeWiki
By severity.
Recent expert groups have suggested simple staging systems that rate mild, moderate, or severe changes based on how deep the lid crease is, how much the lid droops, and how sunken the eye looks. Staging helps with documentation and with tracking improvement after a medication change. PubMed
By age group.
PAP occurs in adults and can also happen in children and young adults on long-term prostaglandin therapy, though it is usually mild to moderate in younger patients. This age-based type reminds us to monitor all ages carefully. PubMed

Causes

PAP is driven by the medication effect itself and by how the medication is used. Each item below is written as a simple “cause or risk factor” so it is easy to scan.

Use of bimatoprost.
Bimatoprost has been frequently linked to PAP and may produce strong changes because it acts powerfully at the FP receptor. EyeWiki
Use of travoprost.
Travoprost can cause similar changes over time because it shares the same FP-receptor action. EyeWiki
Use of latanoprost.
Latanoprost has also been linked to PAP in case series and observational studies. PubMed
Use of tafluprost.
Tafluprost can be involved because it is also an FP-receptor agonist. EyeWiki
Use of unoprostone or other prostaglandin-pathway agents.
Members of the class share a similar risk profile, although strength may vary by drug. EyeWiki
Longer duration of therapy.
The longer the exposure, the more likely visible changes appear, especially after months to years. qa.oftalmoloji.org
Higher effective exposure to the eyelids.
Poor drop technique, overflow onto the skin, and not blotting excess drops increase contact with eyelid tissues. (Common clinical advice; mechanism consistent with local effect.) EyeWiki
Unilateral treatment.
Treating one eye raises the chance of seeing obvious asymmetry, which makes PAP easier to detect on that side. EyeWiki
Greater drug potency at the FP receptor.
Stronger FP-receptor activation leads to stronger anti-fat effects and deeper visible changes. PMC
Frequency and dose.
Using more than prescribed or using extra doses increases tissue exposure and risk. (Dose–exposure principle; consistent with class effect.) EyeWiki
Thin or delicate periorbital fat at baseline.
People with little eyelid fat to start with can show changes sooner. (Clinical observation echoed in reviews.) EyeWiki
Older age.
Age-related fat loss can add to drug effects and make PAP more noticeable. EyeWiki
Tight or deep upper-lid anatomy.
Certain eyelid shapes show crease deepening more clearly when fat shrinks. EyeWiki
Rubbing the eyelids after instillation.
Rubbing spreads the drop over the skin and may increase local exposure. (Technique-related risk; consistent with local action.) EyeWiki
High skin absorption or sensitive skin.
Some people absorb more drug through the eyelid skin and show changes sooner. (Explained in reviews as variability in local response.) EyeWiki
Preservative does not fully explain PAP.
Both preserved and preservative-free prostaglandins have been linked to PAP, so the active drug plays the main role. EyeWiki
Co-medications do not protect against PAP.
Using other glaucoma drops does not remove the prostaglandin effect on fat cells. (Class effect; mechanism data support adipose pathway.) PMC
Higher local retention on eyelid skin.
Occlusion from makeup, ointment, or skin creams right after drops may increase contact time. (Technique factor; consistent with local exposure.) EyeWiki
Genetic or tissue-level sensitivity.
Differences in FP-receptor pathways may make some people more sensitive to fat loss. (Mechanistic inference from FP-receptor studies.) Nature
Choice of non-FP alternative can avoid PAP.
Omidenepag isopropyl, an EP2-receptor agonist, has not been associated with PAP in available reports, highlighting the FP pathway as the key driver. EyeWiki

Symptoms

The upper eyelid fold looks deeper than before.
Many people notice a new or higher crease in the upper lid on the side using the drops. This is often the first sign they see. EyeWiki
The upper eyelid looks droopy.
The lid can sit lower and may cover part of the pupil in some cases, which can feel like heaviness. EyeWiki
The eye looks a little sunken.
A mild inward shift of the eye position can make the orbit look hollow or tight. EyeWiki
The lower-lid “bags” look flatter.
People who used to have puffy lower lids can look slimmer below the eye. EyeWiki
The eyelids may feel firm or tight.
Some people describe tight eyelids, which matches the exam finding of a snug orbit. qa.oftalmoloji.org
Eyelashes look longer or thicker.
Lash growth and thickening are common class effects and often noticed in the mirror. EyeWiki
The skin around the eyes can look darker.
Periorbital hyperpigmentation may appear gradually. EyeWiki
One eye looks different from the other.
Asymmetry is more obvious when only one eye is treated. EyeWiki
Trouble with the top part of vision when the lid is low.
A droopy lid can shade the top visual field in some people. EyeWiki
Eyes look more tired in photos.
Patients often pick up the change by comparing old pictures. Lippincott Journals
Mild cosmetic concern or self-consciousness.
People sometimes feel unhappy about the new look, even if the eye itself is healthy. qa.oftalmoloji.org
Difficulty with contact lens comfort or fit.
A tighter orbit and lid can change comfort for some wearers. (Clinical observation aligned with “tight orbit” description.) qa.oftalmoloji.org
No clear symptoms at all.
Many people feel fine and only the eye doctor notices the change during routine exam. EyeWiki
Applanation tonometry feels different.
The doctor may find eye pressure measurement trickier because the orbit feels tight. Patients may notice extra manipulation during testing. EyeWiki
Skin redness or visible lid vessels.
Some see small vessels on the lid skin become more visible. EyeWiki

Diagnostic tests

Important note: PAP is mainly a clinical diagnosis. That means doctors make the diagnosis by history and exam after prostaglandin exposure. Lab tests are usually not needed for PAP itself. Imaging and lab work are sometimes done to rule out other diseases that can mimic a sunken eye or a droopy lid, such as thyroid eye disease, orbital disease, or a nerve or muscle problem. EyeWiki

A) Physical examination tests

Face-to-face inspection in good light.
The doctor looks for a deeper upper-lid fold, eyelid droop, slimmer lower-lid bags, and visible lid vessels. They compare both sides and check old photos if possible. This simple look often gives the answer. EyeWiki
Palpebral fissure height measurement.
The doctor measures the vertical opening of each eye. A smaller opening can point to eyelid droop and tightness. This is quick and painless.
Margin reflex distance 1 (MRD1).
The doctor measures the distance from the corneal light reflex to the upper lid margin. A smaller number means more droop. This helps track change over time.
Upper-lid crease height measurement.
The height of the eyelid crease from the lash line is measured. A higher crease suggests fat loss under the lid skin and matches the deeper fold described in PAP. EyeWiki
Lower-lid steatoblepharon assessment.
The doctor gently looks for the fullness of lower-lid fat pads. Loss of the pad fullness supports PAP and can be documented for follow-up. EyeWiki
Eyelash exam.
The doctor notes lash length, thickness, and direction. This supports a prostaglandin effect when seen with other signs. EyeWiki
Skin and iris color check.
The doctor looks for darker lid skin and any iris color change. These findings help confirm drug exposure effects. EyeWiki

B) Manual tests and simple tools

Levator function test.
The doctor measures how far the upper lid moves from down-look to up-look while holding the brow still. Poor movement can explain droop and helps separate lid muscle issues from other causes. EyeWiki
Lid distraction test.
The doctor gently pulls the lower lid away from the eye to see how tight it is. A tight lid can fit with the “tight orbit” feel seen in PAP. qa.oftalmoloji.org
Snap-back test.
The doctor pulls the lower lid down and releases it. A quick snap back suggests normal tone; a delayed snap suggests laxity. This helps document lid mechanics in a simple way.
Hertel exophthalmometry.
This small measuring device checks how far the eye sits forward or backward. A slightly lower reading supports enophthalmos in PAP, especially when compared side to side and with old records. EyeWiki
Slit-lamp biomicroscopy.
The doctor uses the microscope to look closely at eyelid edges, lashes, skin, and the eye surface. It also helps document blood vessels and pigmentation changes. EyeWiki

C) Lab and pathological tests — usually not needed for PAP, but used to rule out mimics

Thyroid function tests (TSH, free T4 ± antibodies).
These tests look for thyroid eye disease when exam features are unclear. A normal result supports PAP when the history fits. (Differential diagnosis use.) EyeWiki
Inflammatory markers or autoimmune screens when indicated.
If there is pain, redness, or swelling out of proportion, tests can exclude inflammatory orbit disease. Normal tests again nudge the diagnosis toward medication-related change. (Differential use.) EyeWiki
Pathology of eyelid fat (rarely done).
If surgery is performed for another reason, tissue may show smaller fat cells rather than fewer fat cells, which supports fat atrophy rather than inflammation or scarring. EyeWiki

D) Electrodiagnostic tests — rarely used, only to exclude other problems

Single-fiber EMG for suspected myasthenia gravis.
If eyelid droop fluctuates during the day or improves with rest or cooling, doctors may test for myasthenia. A negative test in the right setting moves the diagnosis back toward PAP. (Rule-out test.)
Nerve conduction or EMG for neuromuscular disease.
If the story suggests a nerve or muscle problem unrelated to drops, testing can help. A normal result again makes PAP more likely when the medication history is strong. (Rule-out test.)

E) Imaging tests

External photography with standardized views.
Careful photos document crease depth, lid height, lower-lid fullness, and symmetry. Photos help show change over time and help patients see improvement after a switch in therapy. EyeWiki
Orbital MRI or CT when needed.
Imaging is not routine but can show smaller orbital fat pads and can rule out tumors, trauma, or other orbital disease. MRI studies have measured fat loss in PAP. PMC
Ultrasound biomicroscopy or anterior segment OCT (adjunctive).
These tools are not standard for PAP but can help in selected cases to study lid or orbital soft tissues as part of a broader work-up. They support documentation when the diagnosis is uncertain after clinical exam.

Non-pharmacological treatments

These steps try to reduce exposure around the eyelids, support appearance, lower your need for prostaglandins, or guide safe alternatives. Each item includes description, purpose, and mechanism in simple words.

Stop the prostaglandin under medical guidance
Description: Your eye specialist may stop the FP-agonist drops if PAP is significant.
Purpose: Remove the trigger.
Mechanism: Without FP-receptor stimulation, the signals that shrink fat and remodel tissues fade, and features may partly reverse over time. PubMed
Switch to a non-FP glaucoma option
Description: Your doctor may replace the prostaglandin with a non-FP drug (see drug section below) or with laser treatment.
Purpose: Keep eye pressure controlled without the same PAP risk.
Mechanism: Avoids FP-receptor effects linked to fat loss and tissue tightening. EyeWiki
Consider an EP2-agonist (where available)
Description: EP2-agonist drops (e.g., omidenepag isopropyl, available in some countries) may be used instead of FP drugs.
Purpose: Lower pressure while reducing PAP risk.
Mechanism: Works through a different receptor (EP2), which is not linked to PAP in current studies. PubMedPMC
Selective Laser Trabeculoplasty (SLT)
Description: In-office laser to the eye’s drainage angle.
Purpose: Reduce or eliminate the need for daily pressure-lowering drops.
Mechanism: Improves fluid outflow in the eye so pressure drops without using FP agonists.
Meticulous drop-instillation technique
Description: Put in one drop, then press the inner corner (punctal occlusion) for 1–2 minutes and gently blot the excess from the lids/skin.
Purpose: Reduce drug running onto the skin.
Mechanism: Less drug contacting eyelid skin means less local FP stimulation around the orbit.
Use single-use, preservative-free units when possible
Description: Some non-FP options and even certain prostaglandins come in preservative-free forms.
Purpose: Reduce irritation and rubbing, which can worsen the cosmetic look.
Mechanism: Fewer preservatives on the skin surface lowers inflammation signals.
Avoid eyelash “serums” that contain PGA-like ingredients
Description: Lash-growth cosmetics may use bimatoprost-like or prostaglandin-like molecules.
Purpose: Prevent extra exposure that can worsen PAP.
Mechanism: Avoids additional FP-like stimulation to the eyelid area. PubMed
Baseline and follow-up photography
Description: Standardized close-ups in the same lighting and angles.
Purpose: Detect subtle changes early.
Mechanism: Visual tracking prompts timely therapy changes.
Avoid chronic eye rubbing and heavy pressure on lids
Description: Reduce mechanical stress to eyelids (including side-sleeping face pressure).
Purpose: Protect thin tissues.
Mechanism: Less stress may limit worsening of droop and tissue remodeling.
Eyelid/skin care and sun protection
Description: Gentle cleansing, sunscreen, and avoiding irritants or harsh retinoids near the eyelids.
Purpose: Protect thin periorbital skin, keep color even.
Mechanism: Limits inflammation and pigment stimulation.
Treat dry eye and blepharitis
Description: Lubrication, eyelid hygiene, warm compresses for the lid margins—not to reverse PAP, but to reduce irritative rubbing.
Purpose: Reduce behaviors that aggravate appearance changes.
Mechanism: Calm surface = less rubbing = less tissue strain.
Makeup camouflage if desired
Description: Concealers, soft contouring, and lash styling by a professional.
Purpose: Hide asymmetry and hollowness.
Mechanism: Optical tricks reduce the visible depth of the sulcus.
Lifestyle: don’t smoke
Description: Stop tobacco.
Purpose: Smoking ages skin and impairs tissue repair.
Mechanism: Better blood flow and collagen health.
Optimize sleep and stress
Description: Regular sleep, stress reduction.
Purpose: Puffiness swings can make hollows look worse.
Mechanism: Stable fluids and cortisol patterns keep eyelid contour steadier.
Weight stability
Description: Avoid rapid weight loss.
Purpose: Orbital fat shrinks with overall fat loss and can magnify PAP hollowness.
Mechanism: Steady nutrition supports subcutaneous volume.
Hyaluronic-acid (HA) filler consultation (non-surgical office procedure)
Description: Gel fillers placed by an oculoplastic surgeon in tear trough/upper lid sulcus.
Purpose: Restore volume and smooth the hollow.
Mechanism: HA attracts water and adds physical volume; reversible with hyaluronidase if needed.
Autologous fat grafting consult
Description: Your own fat is transplanted to the hollow area.
Purpose: Longer-lasting volume in selected patients.
Mechanism: Fat cells add bulk; some may survive long-term.
Energy-based skin tightening only when appropriate
Description: Gentle devices chosen by an eyelid specialist.
Purpose: Improve fine lines or mild laxity that accentuates hollows.
Mechanism: Controlled collagen remodeling; note: this does not regrow lost orbital fat.
Ptosis evaluation
Description: If droop is functionally or cosmetically significant, an oculoplastic surgeon can advise.
Purpose: Decide if surgery is helpful.
Mechanism: Lifting the lid margin can reduce the “tired” look.
Team care with glaucoma specialist
Description: Coordinate pressure control and appearance goals.
Purpose: Balance vision protection with quality of life.
Mechanism: Joint planning leads to safe switching or laser/operative options at the right time.

Drug treatments

(classes, typical dosing, timing, purpose, mechanism, common side effects)

Doses below are typical label-based ranges; your own plan may differ. Use only under your eye doctor’s guidance.

Netarsudil 0.02% (Rho-kinase/NET inhibitor) — 1 drop QHS
Purpose: Lower eye pressure without FP-receptor stimulation.
Mechanism: Increases trabecular outflow and reduces episcleral venous pressure.
Side effects: Conjunctival redness, cornea verticillata; usually mild. FDA Access DataNCBI
Timolol 0.25–0.5% (β-blocker) — 1 drop BID (sometimes QD gel)
Purpose: Proven non-FP first-line/adjunct option.
Mechanism: Reduces aqueous humor production.
Side effects: Can affect heart/lungs; avoid in asthma, certain heart issues (doctor screens first).
Brimonidine 0.1–0.2% (α2-agonist) — 1 drop TID or BID
Purpose: Alternative/adjunct to lower pressure.
Mechanism: Lowers production and increases uveoscleral outflow.
Side effects: Redness, fatigue, dry mouth; rare allergy with chronic use.
Dorzolamide 2% (topical carbonic anhydrase inhibitor) — 1 drop TID or BID
Purpose: Non-FP alternative or add-on.
Mechanism: Lowers aqueous production by blocking carbonic anhydrase.
Side effects: Bitter taste, stinging, rare allergy.
Brinzolamide 1% (topical CAI) — 1 drop TID or BID
Purpose/Mechanism/Side effects: Similar to dorzolamide; may sting less for some.
Simbrinza® (brinzolamide/brimonidine fixed combo) — 1 drop TID or BID
Purpose: Two mechanisms in one bottle; no FP activity.
Mechanism: CAI + α2 synergy.
Side effects: Redness, taste disturbance, fatigue/drowsiness in some.
Brimonidine/Timolol fixed combo — 1 drop BID
Purpose: Potent non-FP combination.
Mechanism: α2 + β-blocker.
Side effects: Combine the cautions of both ingredients; doctor screens cardiopulmonary risks.
Dorzolamide/Timolol fixed combo — 1 drop BID
Purpose: Convenient non-FP pair.
Mechanism: CAI + β-blocker.
Side effects: As above (taste disturbance, cardiopulmonary screening).
Oral Acetazolamide 125–250 mg up to QID (short-term/bridge)
Purpose: Temporary pressure control during switch or while arranging laser/surgery.
Mechanism: Systemic CAI lowers aqueous production.
Side effects: Tingling, frequent urination, stomach upset, low potassium; not for long-term routine without close monitoring.
Omidenepag isopropyl 0.002% (EP2 agonist) — 1 drop QD where available
Purpose: Pressure lowering without FP-receptor stimulation, used in some countries.
Mechanism: EP2 receptor action; clinical studies show QD dosing is effective.
Side effects: Conjunctival hyperemia and mild discomfort in some, but PAP risk appears lower than with FP drugs. PMC+1

Important: “Latanoprostene bunod” and other FP-pathway prostaglandins still act at or near the FP receptor and can trigger PAP; they are not solutions for PAP. If you had PAP, ask about non-FP options or laser. EyeWiki

Dietary molecular supplements

There is no supplement proven to reverse PAP. These options may support skin, collagen, microcirculation, or general tissue health. Discuss with your doctor, especially if you have other conditions or take blood thinners.

Omega-3 (EPA/DHA) — 1–2 g/day combined EPA+DHA
Function: Supports tear film and microvascular health.
Mechanism: Anti-inflammatory lipid mediators may help comfort and reduce rubbing.
Vitamin C — 500–1000 mg/day
Function: Collagen support and antioxidant effect.
Mechanism: Cofactor for collagen cross-linking in skin.
Collagen peptides — 2.5–10 g/day
Function: Skin elasticity support.
Mechanism: Peptides may stimulate dermal collagen production.
Hyaluronic acid (oral) — 120–240 mg/day
Function: Skin hydration.
Mechanism: Water-binding glycosaminoglycan may improve moisture balance.
Coenzyme Q10 — 100–200 mg/day with fat
Function: Mitochondrial antioxidant support.
Mechanism: Helps cellular energy and reduces oxidative stress.
Lutein + Zeaxanthin — 10 mg + 2 mg/day
Function: Ocular antioxidant support.
Mechanism: Carotenoids concentrate in macula; overall eye health.
Zinc — 10–25 mg/day (avoid excess; copper balance)
Function: Collagen remodeling enzymes.
Mechanism: Cofactor for many matrix enzymes.
Selenium — 55–100 mcg/day
Function: Antioxidant enzyme support.
Mechanism: Part of glutathione peroxidases.
Resveratrol — 150–500 mg/day
Function: General antioxidant signaling.
Mechanism: Influences sirtuin pathways; theoretical skin benefits.
Protein sufficiency — 1.0–1.2 g/kg/day (adjust individually)
Function: Tissue repair and maintenance.
Mechanism: Provides amino acids for collagen and extracellular matrix.

Again, these do not replace medication changes, laser, or procedures that actually address PAP.

Regenerative / stem-cell drugs

There are no approved “immunity-booster drugs,” stem-cell drugs, or regenerative pills that safely and specifically reverse PAP. Offering “six stem-cell drugs with doses” would be misleading and unsafe. What is used are procedures that restore volume or stimulate collagen, performed by trained oculoplastic surgeons:

Hyaluronic-acid filler injections (office procedure; not a pill)
Function: Replace lost volume; reversible.
Mechanism: Physical gel fill; attracts water.
Dose: Tailored by injector (measured in syringes), not self-dosed.
Autologous fat grafting (surgical)
Function: Longer-term volume.
Mechanism: Transplanted fat survives and fills hollows; some resorption expected.
Poly-L-lactic acid (biostimulatory filler) in select cases
Function: Collagen stimulation over months.
Mechanism: Particle-driven fibroblast activation.
Platelet-rich plasma (PRP) adjunct (select cosmetic settings)
Function: Growth-factor concentrate for skin quality.
Mechanism: Platelets release growth factors that can support dermal remodeling.
Ptosis repair (levator advancement)
Function: Lift droopy lid to open eye and balance symmetry.
Mechanism: Tightens or advances the lifting muscle.
Upper-lid blepharoplasty when indicated
Function: Remove/reshape redundant skin/fat pads if present.
Mechanism: Surgical contouring by an oculoplastic specialist.

If someone advertises “stem-cell eye drops” or injections to cure PAP, be cautious. These are not approved for PAP and may be risky. Ask for peer-reviewed evidence and regulatory approval first.

Surgeries/procedures

Selective Laser Trabeculoplasty (SLT)
Procedure: Quick in-office laser to the drainage angle.
Why: Lowers pressure to remove or reduce the need for FP-drops that trigger PAP.
Minimally Invasive Glaucoma Surgery (MIGS)
Procedure: Tiny stents or angle procedures done during cataract surgery or alone.
Why: Improve outflow and de-emphasize daily drops long-term.
Trabeculectomy or Tube Shunt
Procedure: Creates a new drainage pathway for eye fluid.
Why: For tougher glaucoma, to control pressure mostly without prostaglandins.
Hyaluronic-acid filler to upper-lid sulcus/tear trough
Procedure: Office injection by an oculoplastic surgeon.
Why: Immediate cosmetic volume replacement with reversibility.
Autologous fat grafting or ptosis repair
Procedure: Surgical volume restoration or lid lifting.
Why: Longer-lasting correction when hollows or droop remain after drug changes.

Preventions

If you are a candidate, consider SLT as first-line to reduce drop dependence.
If drops are needed, start with a non-FP option when PAP risk is a concern.
Avoid “one-eye only” FP therapy long term; asymmetry becomes obvious.
Use correct drop technique (one drop, punctal occlusion, blot excess).
Do not add lash serums with prostaglandin-like ingredients. PubMed
Ask about EP2 agonists or netarsudil as alternatives where available. PMCFDA Access Data
Use preservative-free options when possible to limit irritation and rubbing.
Schedule photo check-ins to catch early changes.
Avoid chronic eye rubbing and heavy pressure on the lids during sleep.
Stop smoking and keep nutrition/sleep steady to support skin health.

When to see a doctor

Right away if you notice new eyelid hollowness, droop, or asymmetry, especially if you started or changed prostaglandin drops recently.
Soon if family/friends notice your eyes look “sunken,” if glasses fit differently on one side, or if makeup sits oddly in a new crease.
Anytime you feel unhappy with appearance changes while on glaucoma therapy: book visits with both your glaucoma specialist (to plan non-FP control) and an oculoplastic surgeon (to discuss volume restoration or ptosis options).
Urgently if you have worsening vision, severe eye pain, light sensitivity, or sudden eyelid swelling/redness, as these are not typical of PAP and need immediate care.

Foods to favor and to limit/avoid

What to eat (support skin/collagen and steady fluids):

Fatty fish (salmon, sardines) for omega-3s.
Citrus and berries for vitamin C.
Eggs, lean meats, legumes for protein and amino acids.
Leafy greens for lutein/zeaxanthin.
Nuts/seeds (walnuts, flax, chia) for healthy fats and minerals.
Tomatoes and peppers for antioxidants.
Avocado for healthy fats and vitamin E.
Greek yogurt/cottage cheese for protein.
Whole grains for steady energy (avoid weight swings).
Plenty of water for stable hydration.

What to limit/avoid (to reduce puff/sag swings or skin stress):

Excess alcohol (dehydrates skin).
High-salt foods (worsen morning puffiness, exaggerate hollows later).
Ultra-processed sweets (collagen-damaging glycation).
Trans fats.
Smoking/vaping (not a food, but crucial to avoid).
Excess vitamin A/retinoids around eyelids (can irritate).
Crash diets (rapid fat loss accentuates hollows).
Energy drinks (sleep disruption; fluid swings).
Very low-protein diets (limits tissue repair).
Unregulated “miracle” supplements claiming eye fat regrowth.

FAQs

1) What exactly is PAP?
Changes around the eyes caused by prostaglandin-type glaucoma drops, especially FP-receptor agonists. It often looks like deeper upper-lid hollows, mild eye sinking, and droopy lids. EyeWiki

2) Is PAP dangerous to my sight?
PAP itself is mostly cosmetic, but the drops that cause it are used to protect vision by lowering pressure. Work with your doctor to keep pressure controlled while addressing PAP.

3) Does PAP go away if I stop the drops?
In many patients, yes—partially or fully, but it can take months and results vary. PubMed

4) Can I switch to another medicine to avoid PAP?
Often yes. Non-FP options like netarsudil, timolol, CAIs, α2-agonists, or laser can control pressure without the same PAP risk. FDA Access Data

5) Are EP2-agonists better for PAP?
Current studies suggest EP2 agonists (e.g., omidenepag isopropyl) lower pressure without triggering PAP, but availability varies by country. PubMed

6) Why do prostaglandins change eyelids?
FP-receptor signals reduce fat-cell formation and remodel tissues, leading to volume loss and a tighter look. PMCNature

7) I used a lash serum and now see hollows—could it be PAP?
Yes. Lash serums with prostaglandin-like molecules have been linked to periorbital volume loss. Stop and see your doctor. PubMed

8) Will hyaluronic-acid filler fix it?
Filler can restore volume quickly. It does not treat the cause, and it must be done by an expert in the eyelid area.

9) Is fat grafting permanent?
Some grafted fat survives and gives long-lasting volume, but results vary and touch-ups may be needed.

10) Can I keep using prostaglandins in both eyes to “match” them?
That prevents asymmetry but does not prevent PAP—it simply makes both sides change. Safer is to discuss non-FP pressure control. EyeWiki

11) How quickly can PAP appear?
It can appear within weeks to months in some people, but timing varies widely. Review of Ophthalmology

12) Are there creams that reverse PAP?
No topical cosmetic cream is proven to rebuild orbital fat. Some may improve skin texture only.

13) Are there approved stem-cell drugs for PAP?
No. There are no approved stem-cell drugs to reverse PAP. Be wary of unproven treatments.

14) Can surgery for glaucoma help me avoid PAP?
Yes. SLT, MIGS, or filtering surgery can cut or eliminate daily drop use and therefore FP exposure.

15) What is the safest next step?
See your glaucoma specialist to switch away from FP agents and your oculoplastic surgeon to plan volume or lid solutions tailored to you.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.